Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib vs placebo in RAI-refractory differentiated thyroid cancer
2009-012007-25Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC), papillary thyroid cancer (PTC), follicular carcinoma (FTC) and 1 more comparing Sorafenib (Nexavar) with Placebo (2 arms). Primary endpoint: Progression-Free Survival. Started Sep 2009; status: completed.
02
Drugs
sorafenib
03
Conditions
Radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC)papillary thyroid cancer (PTC)follicular carcinoma (FTC)Hürthle cell carcinoma of the thyroid (HCC)
Beyond the preview
Go deeper on 2009-012007-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012007-25.